Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
CaixaBank $2 billion notes offering under $7.5 billion U.S. MTN program
The offering involved senior non-preferred callable fixed-to-floating-rate notes due 2030 and 2035
CK Hutchison Holdings $2 billion notes offering
We advised CK Hutchison Holdings on its Rule 144A / Regulation S notes offering
Province of Ontario $1.5 billion global bond offering
The investment-grade bonds are due 2034
Province of British Columbia $2.5 billion global bond offering
The investment-grade bonds are due 2029
General Mills €1 billion notes offering
The investment-grade notes are due 2030 and 2034
Korro Bio $70 million private placement
The PIPE consists of common stock
Baicha Baidao HK$2.6 billion IPO
We advised Baicha Baidao on its IPO and HKEX listing
TScan Therapeutics $150 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Cohen & Steers $100 million at-the-market offering
The shares are listed on the NYSE
Intra-Cellular Therapies $500 million stock offering
The shares are listed on the Nasdaq Global Select Market